LIVEN stock snapshot.
Liven Pharma Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
LIVEN vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
LIVEN Liven Pharma Limited | n/a | 4.85 | -0.92% | -459.22% | 18.66% | PKR 4.0bn | -1.41% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| HALEON →Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
Liven Pharma Limited
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.
Turn LIVEN from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.